Phase 3 Ixo-Vec Program Advances

By
Jim Gallagher, senior managing editor
May 14, 2026
4 min

Retinal Physician

Objective:

To evaluate the efficacy and safety of ixoberogene soroparvovec (ixo-vec) in treating neovascular age-related macular degeneration (nAMD) through sustained aflibercept expression after a single injection, which may significantly reduce treatment burden.

Key Findings:

Persistent aflibercept expression was detected 4 to 5 years post-treatment in the OPTIC trial.
Patients averaged fewer than 2 injections annually after receiving ixo-vec, compared to approximately 10 prior to enrollment, indicating a significant reduction in treatment burden.
Visual acuity and central subfield thickness remained stable, with reduced treatment burden observed in a population previously requiring high-frequency injections.

Interpretation:

The findings suggest that ixo-vec may provide a durable treatment option for nAMD, addressing the variability and high treatment burden associated with current anti-VEGF therapies, which often require frequent dosing.

Limitations:

The studies primarily involved patients with high treatment burden, which may not represent all nAMD populations and could limit the generalizability of the findings.
Long-term safety and efficacy data are still pending from ongoing phase 3 trials.

Conclusion:

Ixo-vec shows promise as a long-term solution for nAMD, with significant reductions in treatment frequency and stable visual outcomes, addressing a critical need in the management of this condition.

Phase 3 Ixo-Vec Program Advances

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Phase 3 Ixo-Vec Program Advances

Related Content

Magnesium & DR Risk

EYP-1901 for Retinal Exudative Diseases

FDA Clears Nocturnal IOP Device